Achillion

J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market
J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market
Endpoints
JNJ
Achillion
hepatitis C
odalasvir
ACH-3102
Flag link:
J&J advances through PhII with a promising hep C triple and 100% cure rate
J&J advances through PhII with a promising hep C triple and 100% cure rate
Endpoints
JNJ
hepatitis C
clinical trials
odalasvir
AL-335
Olysio
Achillion
Flag link:
8 Major FDA Decisions and Trial Results to Watch for in September
8 Major FDA Decisions and Trial Results to Watch for in September
24/7 Wall St
FDA
Achillion
odalasvir
AL-335
simeprevir
Amarin
Vascepa
Array Biopharma
binimetinib
Mast Therapeutics
vepoloxamer
Novavax
Threshold Pharmaceuticals
tarloxotinib
Flag link:
3 Biotechs Expecting Market-Moving Trial Results Soon
3 Biotechs Expecting Market-Moving Trial Results Soon
Motley Fool
biotech
Ophthotech
Achillion
Kite Pharma
odalasvir
JNJ
Fovista
KTE-C19
Flag link:
Achillion's Pipeline Strengthens, With Near-Term Potential Catalysts
Achillion's Pipeline Strengthens, With Near-Term Potential Catalysts
Seeking Alpha
Achillion
ACH-4471
JNJ
hepatitis C
Flag link:
Buying These 2 Drug Developers Would Make a Lot of Sense for Johnson & Johnson
Buying These 2 Drug Developers Would Make a Lot of Sense for Johnson & Johnson
Motley Fool
JNJ
drug development
M&A
Geron
Achillion
Flag link:
3 Small-Cap Biotech Stocks With Big News Coming in 2016
3 Small-Cap Biotech Stocks With Big News Coming in 2016
Motley Fool
biotech
Ophthotech
Fovista
andexanet alfa
Portola Pharmaceuticals
ACH-3102
Achillion
Flag link:
4 Key FDA Decisions Expected By Year End
4 Key FDA Decisions Expected By Year End
24/7 Wall St
FDA
Achillion
hepatitis C
Biocryst
OPuS-2
BCX4161
Tetraphase Pharmaceuticals
Lucitanib
Clovis Oncology
Flag link:
Is Gilead Sciences' Dominance in Hepatitis C Unstoppable?
Is Gilead Sciences' Dominance in Hepatitis C Unstoppable?
Motley Fool
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
AbbVie
Viekira Pak
Achillion
Flag link:
Johnson & Johnson And Achillion Pharmaceuticals May Offer Fastest 100% Cure With Their HCV Combo
Johnson & Johnson And Achillion Pharmaceuticals May Offer Fastest 100% Cure With Their HCV Combo
Bidness, ETC
JNJ
Achillion
hepatitis C
Sovaldi
Gilead Sciences
ACH-3102
odalasvir
Flag link:
What Will Gilead Buy Next? 4 Possible Targets
What Will Gilead Buy Next? 4 Possible Targets
Investors.com
Gilead Sciences
M&A
Incyte
Vertex Pharmaceuticals
Bristol-Myers Squibb
Achillion
Flag link:
5 Drugs That Investors May Be Undervaluing
5 Drugs That Investors May Be Undervaluing
Motley Fool
Amicus Therapeutics
Galafold
Receptos
ozanimod
GS-5816
Gilead Sciences
ACH-3102
Achillion
Ophthotech
Fovista
Flag link:
Will the J&J Deal With Achillion Transform the Hep C Market?
Will the J&J Deal With Achillion Transform the Hep C Market?
WSJ Pharmalot
JNJ
hepatitis C
Achillion
Flag link:
Achillion partners with J&J to develop hep C drugs
Achillion partners with J&J to develop hep C drugs
Yahoo/Reuters
Achillion
JNJ
R&D
hepatitis C
Flag link:
Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest
Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest
TheStreet.com
M&A
social media
twitter
Gilead Sciences
hepatitis C
Achillion
Flag link:
Achillion Pharmaceuticals reports first-quarter loss but tops expectations
Achillion Pharmaceuticals reports first-quarter loss but tops expectations
Yahoo/AP
Achillion
earnings
Flag link:
Gilead Will Keep Hepatitis C Dominance In Its Grip With Recent Trial Results
Gilead Will Keep Hepatitis C Dominance In Its Grip With Recent Trial Results
Seeking Alpha
Gilead Sciences
Harvoni
hepatitis C
AbbVie
Bristol-Myers Squibb
Merck
Achillion
Flag link:
Should Gilead Sciences, Inc. Be Worried By Achillion Pharmaceuticals?
Should Gilead Sciences, Inc. Be Worried By Achillion Pharmaceuticals?
Motley Fool
Gilead Sciences
Achillion
hepatitis C
Sovaldi
Harvoni
Flag link:
[video]2 Small Biotech Stocks Dreaming Big in Hepatitis C
[video]2 Small Biotech Stocks Dreaming Big in Hepatitis C
Motley Fool
hepatitis C
Regulus
Achillion
Flag link:
Achillion HCV-1 regimen achieves 100% SVR12 at six weeks
Achillion HCV-1 regimen achieves 100% SVR12 at six weeks
Seeking Alpha
Achillion
hepatitis C
ACH-3102
Gilead Sciences
Sovaldi
Flag link: